iRadimed Posts 51-Cent Q3 EPS, Topping Prior Quarter's 41 Cents
IRMD is trading near its 52-week low of $75.75 (10% above the low).
Summary
iRadimed reported third-quarter EPS of 51 cents, up from the 41 cents GAAP it posted in Q2, with adjusted EPS of 55 cents. Third-quarter revenue came in at $24.2M, a meaningful step up for a company whose Q2 revenue grew only 0.5% to $20.5M. The Q2 story was the launch of the 3870 MR IV pump, with over 70% of new orders tied to it; a stronger Q3 print suggests that product ramp is starting to pay off. Looking ahead, the company sees fourth-quarter EPS of 53c to 57c and adjusted EPS of 57c to 61c.
At the time of this announcement, IRMD was trading at $83.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $75.75 to $107.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.